108 related articles for article (PubMed ID: 12562453)
1. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole.
Edsbäcker S; Larsson P; Bergstrand M
Aliment Pharmacol Ther; 2003 Feb; 17(3):403-8. PubMed ID: 12562453
[TBL] [Abstract][Full Text] [Related]
2. A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone.
Edsbäcker S; Nilsson M; Larsson P
Aliment Pharmacol Ther; 1999 Feb; 13(2):219-24. PubMed ID: 10102953
[TBL] [Abstract][Full Text] [Related]
3. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules.
Edsbäcker S; Larsson P; Wollmer P
Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1357-62. PubMed ID: 12468958
[TBL] [Abstract][Full Text] [Related]
4. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.
Edsbäcker S; Bengtsson B; Larsson P; Lundin P; Nilsson A; Ulmius J; Wollmer P
Aliment Pharmacol Ther; 2003 Feb; 17(4):525-36. PubMed ID: 12622761
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension.
Song JC; Quercia RA; Fan C; Tsikouris J; White CM
Am J Health Syst Pharm; 2001 Apr; 58(8):689-94. PubMed ID: 11329761
[TBL] [Abstract][Full Text] [Related]
7. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
Edsbäcker S; Andersson T
Clin Pharmacokinet; 2004; 43(12):803-21. PubMed ID: 15355126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis.
Wo JM; Eversmann J; Mann S
Aliment Pharmacol Ther; 2010 Feb; 31(4):516-22. PubMed ID: 19925497
[TBL] [Abstract][Full Text] [Related]
10. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
[TBL] [Abstract][Full Text] [Related]
11. Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.
Kirkpatrick C; Buck H; Ellis S
J Aerosol Med; 2003; 16(1):31-6. PubMed ID: 12737682
[TBL] [Abstract][Full Text] [Related]
12. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Röhss K
Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers.
Hussein RF; Lockyer M; Hammami MM
Arzneimittelforschung; 2007; 57(2):101-5. PubMed ID: 17396620
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers.
Joti JJ; Nahar K; Hasan A; Azad MA; Ullah MA; Islam SM; Hasnat A
Arzneimittelforschung; 2009; 59(4):171-5. PubMed ID: 19517893
[TBL] [Abstract][Full Text] [Related]
19. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
20. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
Dong H
Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):533-6. PubMed ID: 11798692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
